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Background:  Brain  natriuretic  peptide  (BNP)  and  amino-terminal  proBNP  (NT-proBNP)  are  useful
biomarkers  for  diagnosis  and  prediction  of  prognosis.  Both  of  these  peptides  are elevated  in  patients
with  chronic  kidney  disease  (CKD),  but  there  is  no  evidence  as to  which  peptide  is  the  more  suitable
biomarker  in  patients  with  severe  renal  dysfunction.
Methods  and results:  This  retrospective  cohort  study  evaluated  patients  with  cardiovascular  diseases
(64.9  ± 11.7  years,  mean  ± SD).  The  end  points  were  all-cause  death and  a composite  end  point  of all-
cause  death,  nonfatal  myocardial  infarction,  nonfatal  stroke,  hospitalization  for severe  heart  failure,  and
initiation of  hemodialysis.  Baseline  plasma  BNP  and  NT-proBNP  levels,  expressed  as  log-transformed
data,  were  closely  correlated  in  patients  with  CKD  stages  1–3  (n = 998)  (r2 =  0.870,  p  < 0.001),  whereas
for CKD  stages  4–5  (n =  85)  there  was  a signiﬁcant  but weaker  correlation  (r2 = 0.209,  p < 0.001).  During
follow-up  periods  (51.3  ±  0.4  months),  132  patients  died  and  202  patients  reached  the  composite  end
point.  The  area  under  the  receiver  operating  characteristic  curve  (AUROC)  for BNP  and  NT-proBNP  were
similar for CKD  stages  1–3. However,  for  CKD  stages  4–5,  the  AUC for  mortality  for  BNP  was  0.713  and
that  for  NT-proBNP  was  0.760,  while  the  AUC  for the  composite  end  point  for BNP  was  0.666  and  that  for
NT-proBNP  was 0.720.
Conclusions:  Both  BNP  and  NT-proBNP  are  useful  biomarkers  for  mortality  and  cardiovascular  events,  but
NT-proBNP  may  be superior  to BNP  for CKD  stages  4–5.
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Heart failure is a leading cause of morbidity and mortality in
estern countries. Its diagnosis and appropriate treatment are
ometimes challenging not only for general practitioners but also
or cardiologists. Testing for plasma levels of brain natriuretic pep-
ide (BNP) and its amino-terminal fragment, N-terminal proBNP
NT-proBNP), has emerged as a useful tool for the diagnosis and
isk stratiﬁcation of patients with heart failure [1–3]. BNP was
riginally isolated from porcine brain, but in humans is exclusively
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synthesized in the heart, and its expression is increased in response
to ventricular wall stress and ﬁlling pressure [4,5]. Thus, plasma
BNP and NT-proBNP levels are elevated in accordance with heart
failure severity.
BNP and NT-proBNP are derived from the same precursor form
of BNP, designated as ProBNP. This precursor consists of 108
amino acid residues and is subsequently cleaved into a C-terminal
32-amino-acid BNP and an N-terminal 76-amino-acid fragment,
NT-proBNP [6,7]. BNP is a mature, biologically active peptide that
exerts its biological actions through its primary signaling receptor,
guanylyl cyclase A [8]. BNP also binds to a clearance receptor and is
degraded by a neutral endopeptidase that is abundantly expressed
on cell surfaces. BNP is therefore cleared by speciﬁc receptors and
a neutral endopeptidase, and non-speciﬁcally cleared by the kid-
neys [9]. In contrast, NT-proBNP is a biologically inert peptide that
is mainly cleared by the kidneys, and not by receptor-mediated
mechanisms. Consequently, BNP and NT-proBNP are produced in
vier Ltd. All rights reserved.
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he same manner but their metabolism is dissimilar, and it is there-
ore likely that plasma levels of NT-proBNP are far more inﬂuenced
y renal function than those of BNP.
Despite the notable differences between the two  peptides, both
ave proven to be useful biomarkers for the diagnosis and risk
tratiﬁcation of heart failure [10–13]. However, some studies have
rovided clinical evidence based on assay systems for BNP, while
thers have focused on NT-proBNP. Of course the proposed cutoff
alues for these peptides can differ signiﬁcantly, and the results are
ot directly comparable because in many clinical settings, includ-
ng chronic kidney disease (CKD), there is no equation relating BNP
nd NT-proBNP.
Given that patients with heart failure usually suffer from chronic
idney disease (CKD), and glomerular ﬁltration rate (GFR) is one of
he strong predictors of cardiovascular events, the renal function –
ssociated equation relating plasma levels of BNP and NT-proBNP
hould be necessary to better understand these peptides’ diagnos-
ic and prognostic values in CKD [14–18]. It also remains unclear
hich peptide is a superior biomarker for cardiovascular events in
atients with CKD [19,20].
In the present study, we simultaneously measured plasma lev-
ls of BNP and NT-proBNP in more than 1000 patients with various
enal functions to calculate the equation that connects the two
eptides, and investigated which peptide was the more suitable
iomarker for predicting cardiovascular events in patients with
KD.
ethods
tudy population
This retrospective cohort study enrolled 1083 consecutive
atients with cardiovascular disease who underwent elective
ardiac catheterization for diagnosis or percutaneous coronary
ntervention at Nara Medical University Hospital between April
004 and August 2008. Patients with acute coronary syndrome,
cute myocarditis, and the acute phase of heart failure were
xcluded. There were 764 males and 319 females aged between 18
nd 90 years (64.9 ± 11.7 years old, mean ± SD). Patients received
egular follow-up care in our hospital outpatient ward or another
linic. Of 1083 patients, 1035 (95.6%) were followed up for a mean
uration of 51.9 ± 13.5 months. Clinical events were analyzed in
une, 2010 using clinical records, phone calls, and letters. We  ﬁrst
alculated the baseline estimated GFR (eGFR) (adjusted for body
urface area as ml/min/1.73 m2) by the three-variable revised equa-
ion of the Modiﬁcation of Diet in Renal Disease equation for GFR in
apanese (eGFR = 194 × serum creatinine−1.094 × age−0.287 × 0.739
if female]) [21]. We  then divided all patients into 4 groups
ased on eGFR (≥90, 60–89, 30–59, <30 ml/min/1.73 m2), accord-
ng to the guidelines of the National Kidney Foundation [22].
nformed consent for participation in the study was  obtained
rom all patients according to a protocol approved by the
nstitutional review board at Nara Medical University (#2002-
09).
nd points
This study had two co-primary end points: all-cause death
nd the composite end point of all-cause death, nonfatal acute
yocardial infarction, nonfatal cerebral infarction, initiation of
ialysis, and hospitalization due to severe heart failure. Here, heart
ailure was classiﬁed as severe when the patient required venti-
ation or mechanical hemodynamic support in the intensive care
nit.logy 61 (2013) 410–416 411
Cardiac catheterization
Left-sided cardiac catheterization was performed, and mean
blood pressure and left ventricular end diastolic pressure (LVEDP)
were measured. Heart rate was  monitored by electrocardiography.
Cardiac output was  measured with a Swan–Ganz catheter. Left ven-
tricular end-diastolic volume (LVEDV), left ventricular end-systolic
volume (LVESV), stroke volume, and left ventricular ejection frac-
tion (LVEF) were measured by left ventriculography.
Blood samples and measurements
Blood samples for measurement of BNP, NT-proBNP, and
creatinine levels were collected at the beginning of cardiac cathe-
terization using a 7F sheath inserted into the patient’s femoral vein
before unfractionated heparin and contrast medium were used.
Blood samples were collected into plastic tubes with ethylene-
diaminetetraacetic acid, and stored in aliquots at −80 ◦C until
analysis. All samples for BNP evaluation were analyzed at the end
of the study. Plasma BNP concentrations were measured with a
speciﬁc radioimmunoassay for human BNP using a commercial
kit (Shionogi & Co., Ltd., Osaka, Japan), and those of NT-proBNP
concentrations were measured with an Elecsys proBNP sandwich
immunoassay (Roche Diagnostics, Mannheim, Germany).
Statistical analysis
Data were analyzed using SPSS version 19 (SPSS, IBM, Chicago,
IL, USA). Plasma levels of BNP and NT-proBNP values were nor-
malized by log10 transformation. All results are expressed as the
mean ± S.D, but BNP, NT-proBNP, log BNP, and log NT-proBNP are
expressed as the median (25th–75th percentiles), because these
were not normally distributed. We  compared the two groups’
clinical characteristics with the Wilcoxon rank-sum test, but
comparison between BNP and NT-proBNP was performed with
Mann–Whitney’s U-test. Univariate linear regression analyses were
carried out to evaluate the relationship between BNP or NT-proBNP
and clinical characteristics as continuous variables when appropri-
ate. Multivariate regression analyses were carried out to determine
which variables were independently associated with BNP or NT-
proBNP and the relation between log NT-proBNP and log BNP or
other clinical characteristics. Only variables that were statically sig-
niﬁcant in the univariate analyses were included. We  calculated by
two methods, with and without the inclusion of cardiac catheter-
ization variables.
The sensitivity and speciﬁcity of BNP and NT-proBNP for pre-
dicting mortality and morbidity according to severity of renal
function were determined, and receiver operating characteristic
(ROC) curves were constructed. A value of p < 0.05 was considered
signiﬁcant.
Results
Baseline characteristics of the study population
Table 1 summarizes the baseline characteristics of the total
study population as well as patient subgroups. The causes of car-
diovascular disease were ischemic heart disease in 672 (62.0%)
patients, vasospastic angina in 176 (16.3%), dilated cardiomyopathy
in 85 (7.8%), valvular disease in 63 (5.8%), hypertrophic cardiomy-
opathy in 19 (1.8%), congenital heart disease in 18 (1.7%), and
other cardiovascular disease. The median (25th–75th percentiles)
plasma BNP level was 54.7 (20.3–155.0) pg/ml, and that of plasma
NT-proBNP was  248.0 (73.2–935.0) pg/ml.
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Table  1
Baseline clinical characteristics and laboratory data of the study patients.
All patients CKD 1 CKD 2 CKD3 CKD4–5 p-Value
(n  = 1083) (n = 130) (n = 576) (n = 292) (n = 85)
Age (years) 64.9 ± 11.7 55.7 ± 13.9 63.5 ± 10.8 71.1 ± 8.4 66.8 ± 8.7 <0.001
Gender (male/female) 764/319 88/42 408/168 211/81 56/29
Body mass index (kg/m2) 24.2 ± 3.5 23.9 ± 4.0 24.4 ± 3.4 24.1 ± 3.4 22.7 ± 3.7 <0.001
Serum creatinine (mg/dl) 1.26 ± 1.77 0.58 ± 0.10 0.78 ± 0.12 1.10 ± 0.21 6.13 ± 3.69 <0.001
eGFR  (ml/min/1.73 m2) 65.9 ± 24.6 105.2 ± 16.3 73.4 ± 8.2 49.1 ± 7.8 12.4 ± 9.4 <0.001
Mean  blood pressure (mmHg) 101.3 ± 16.4 101.0 ± 16.6 101.4 ± 15.3 99.9 ± 17.1 106.5 ± 20.3 0.032
Heart  rate (bpm) 70.2 ± 14.0 70.7 ± 12.9 69.7 ± 14.4 70.2 ± 14.0 72.7 ± 13.6 0.276
Cardiac index (l/min/m2) 3.07 ± 0.76 3.36 ± 0.85 3.06 ± 0.72 2.87 ± 0.64 3.40 ± 0.89 <0.001
LV  ejection fraction (%) 56.5 ± 14.0 59.5 ± 12.8 58.1 ± 13.1 53.9 ± 15.0 50.7 ± 15.4 <0.001
LV  end-diastolic pressure (mmHg) 13.1 ± 6.3 12.3 ± 5.4 12.5 ± 5.7 14.0 ± 7.0 15.5 ± 8.4 <0.001
LV  end-diastolic volume index (ml/m2) 74.9 ± 29.3 74.0 ± 19.7 72.4 ± 26.9 75.2 ± 31.4 92.7 ± 42.2 <0.001
LV  end-systolic volume index (ml/m2) 34.7 ± 24.1 31.1 ± 16.9 32.2 ± 21.7 37.2 ± 26.6 48.7 ± 33.8 <0.001
Stroke index (ml/m2) 40.2 ± 12.9 43.0 ± 11.7 40.2 ± 12.4 38.0 ± 12.7 44.0 ± 17.3 <0.001
BNP  (pg/ml) 54.7(20.3–155.0) 28.4(12.1–78.9) 40.1 (17.9–103.0) 110.5 (37.0–215.8) 178.0 (41.7–440.5) <0.001
NT-proBNP (pg/ml) 248.0 (73.2–935.0) 83.5 (33.2–301.0) 160.5 (57.9–569.6) 499.8 (158.0–1387.8) 6220.0 (1317.5–23246.0) <0.001
Etiology of heart failure, n (%)
Ischemic heart diseasea 672 (62.0) 68 (52.3) 343 (59.5) 203 (69.5) 58 (68.2)
Vasospastic angina 176 (16.3) 32 (24.6) 112 (19.4) 29 (9.9) 3 (3.5)
Dilated cardiomyopathy 85 (7.8) 14 (10.8) 41 (7.1) 19 (6.5) 11 (12.9)
Valvelur disease 63 (5.8) 2 (1.5) 36 (6.3) 19 (6.5) 6 (7.1)
Hypertrophic cardiomyopathy 19 (1.8) 1 (0.8) 10 (1.7) 6 (2.1) 2 (2.4)
Congenital heart disease 18 (1.7) 4 (3.1) 9 (1.6) 4 (1.4) 1 (1.2)
Other  50 (4.6) 9 (6.9) 25 (4.4) 12 (4.1) 4 (4.7)
Risk  factor, n (%)
Diabetic mellitus 425 (39.2) 56 (43.1) 216 (37.5) 110 (37.7) 43 (50.6) 0.168
Hypertension 705 (65.1) 73 (56.2) 354 (61.5) 216 (72.9) 65 (76.5) <0.001
Dyslipidemia 533 (49.2) 66 (50.8) 303 (52.6) 135 (46.2) 29 (34.1) <0.001
Smoking 676 (62.4) 80 (61.5) 369 (64.1) 177 (60.6) 50 (58.8) 0.608
Baseline therapy, n (%)
ACE-I 320 (29.5) 37 (30.0) 159 (27.6) 97 (33.2) 25 (29.4) <0.001
ARB  402 (37.1) 38 (29.2) 204 (35.4) 117 (40.1) 43 (50.6) 0.016
ACE-I  or ARB 665 (61.4) 71 (54.6) 344 (59.7) 191 (65.4) 59 (69.4) 0.013
Beta  blocker 222 (20.5) 25 (19.2) 113 (19.6) 64 (21.9) 20 (23.5) 0.145
Calcium antagonist 430 (39.7) 52 (40.0) 223 (38.7) 114 (39.0) 41 (48.2) 0.543
Diuretics 274 (25.3) 21 (16.2) 112 (19.4) 112 (38.4) 29 (34.1) <0.001
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a Ischemic heart disease: without vasospastic angina.
nivariate and multivariate correlation between clinical
arameters and BNP or NT-proBNP
Both BNP and NT-proBNP were positively correlated with
erum creatinine level, heart rate, LVEDV, and LVESV, and
egatively correlated with body mass index (BMI), eGFR,
nd LVEF (Table 2). Proﬁles of correlation coefﬁcients were
imilar for BNP and NT-proBNP. As shown in Table 3, uni-
ariate analyses showed that correlation coefﬁcients in patients
ith an eGFR ≥ 30 ml/min/1.73 m2 were similar to those in
he total patient population (Table 2). Multivariate analyses,
able 2
nivariate regression of BNP and NT-proBNP in all patients.
BNP 
cc p
Age (years) 0.091 
Gender (male/female) −0.002 
BMI  (kg/m2) −0.159 <
BNP  (pg/ml) 
NT-pro BNP (pg/ml) 0.640 <
Cr (mg/dl) 0.352 <
eGFR  (ml/min/1.73 m2) −0.302 <
Mean  BP (mmHg) −0.114 <
Heart  rate (bpm) 0.138 <
CI  (l/min/m2) −0.037 
LVEF  (%) −0.315 <
LVEDP  (mmHg) 0.299 <
LVEDVI (ml/m2) 0.331 <
LVESVI (ml/m2) 0.374 <
SI  (ml/m2) 0.053 however, indicated that plasma BNP levels were signiﬁcantly
correlated with hemodynamic parameters, whereas plasma
NT-proBNP levels were signiﬁcantly correlated with hemody-
namic and renal parameters and age. In patients with an
eGFR < 30 ml/min/1.73 m2, multivariate analyses showed no sig-
niﬁcant correlation between plasma BNP levels and clinical
parameters, but plasma NT-proBNP levels were signiﬁcantly
correlated with LVEDP and BMI, indicating that determinants
of plasma BNP and NT-proBNP levels were not similar in
patients with an eGFR ≥ 30 ml/min/1.73 m2 compared to an
eGFR < 30 ml/min/1.73 m2 (Tables 3 and 4).
NT-proBNP
-Value cc p-Value
0.003 0.005 0.865
0.954 −0.011 0.707
0.001 −0.163 <0.001
0.640 <0.001
0.001
0.001 0.547 <0.001
0.001 −0.346 <0.001
0.001 0.004 0.911
0.001 0.098 0.005
0.283 0.067 0.054
0.001 −0.188 <0.001
0.001 0.212 <0.001
0.001 0.192 <0.001
0.001 0.224 <0.001
0.086 0.017 0.588
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Table  3
Univariate and multivariate regressions in patients with CKD stages 1–3.
BNP NT-proBNP
Univariate Multivariate Univariate Multivariate
cc p-Value cc p-Value cc p-Value cc p-Value
Age (years) 0.205 <0.001 0.196 <0.001 0.193 <0.001 0.167 <0.001
Gender (male/female) 0.041 0.193 0.050 0.117
BMI  (kg/m2) −0.129 <0.001 −0.128 <0.001
Cr  (mg/dl) 0.204 <0.001 0.227 <0.001 0.132 <0.001
eGFR  (ml/min/1.73 m2) −0.223 <0.001 −0.232 <0.001
Mean  BP (mmHg) −0.143 <0.001 −0.080 0.009 −0.163 <0.001 −0.104 0.001
Heart  rate (bpm) 0.198 <0.001 0.174 <0.001 0.209 <0.001 0.153 <0.001
CI  (l/min/m2) −0.152 <0.001 −0.077 0.019 −0.164 <0.001
LVEF  (%) −0.430 <0.001 −0.158 <0.001 −0.433 <0.001 −0.256 <0.001
LVEDP (mmHg) 0.384 <0.001 0.272 <0.001 0.339 <0.001 0.195 <0.001
LVEDVI (ml/m2) 0.409 <0.001 0.258 <0.001 0.349 <0.001 0.158 <0.001
LVESVI (ml/m2) 0.472 <0.001 0.433 <0.001
SI  (ml/m2) 0.041 0.207 −0.022 0.485
Table 4
Univariate and multivariate regressions in patients with CKD stages 4–5.
BNP NT-proBNP
Univariate Multivariate Univariate Multivariate
cc p-Value cc p-Value cc p-Value cc p-Value
Age (years) −0.069 0.531 −0.177 0.104
Gender (male/female) −0.117 0.285 −0.113 0.304
BMI  (kg/m2) −0.262 0.015 −0.366 0.001 −0.344 0.001
Cr  (mg/dl) 0.158 0.149 0.329 0.002
eGFR  (ml/min/1.73 m2) −0.211 0.053 −0.373 <0.001
Mean  BP (mmHg) −0.278 0.019 −0.093 0.440
Heart  rate (bpm) 0.129 0.278 0.226 0.056
CI  (l/min/m2) −0.043 0.723 0.048 0.686
LVEF  (%) −0.323 0.004 −0.380 0.001
LVEDP (mmHg) 0.307 0.009 0.432 <0.001 0.447 <0.001
2 0.249 0.026
0.344 0.002
−0.064 0.572
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Fig. 1. Scatter plot of log BNP and log NT-proBNP according to severity of CKD
stage. In patients with CKD stages 1–3 (n = 998), the equation of the regres-
sion line is as follows: log NT-proBNP (pg/ml) = 0.311 + 1.169 × log BNP (pg/ml)
(r2 = 0.871, p < 0.001). In patients with CKD stages 4–5 (n = 85), log NT-proBNPLVEDVI (ml/m ) 0.300 0.007 
LVESVI (ml/m2) 0.361 0.001 
SI  (ml/m2) 0.026 0.817 
imple linear regression analyses between BNP and NT-proBNP
Although plasma NT-proBNP levels were signiﬁcantly corre-
ated with plasma BNP levels (r2 = 0.640, p < 0.001, Supplemental
ig. S1), scatter plot points were relatively widely distributed,
specially for high levels of the peptides. When simple linear
egression analyses were carried out to evaluate the relation
etween baseline plasma BNP and NT-proBNP levels expressed as
og-transformed data, a close correlation was observed between
NP and NT-proBNP log-transformed data (r2 = 0.719, p < 0.001,
ig. 1). As shown in Fig. 1, scatter plot points representing patients
ith an eGFR < 30 ml/min/1.73 m2 apparently deviated from the
egression line. Simple linear regression analyses were separately
e-performed for patients with eGFRs of ≤30 ml/min/1.73 m2.
n patients with an eGFR ≥ 30 m/min/1.73 m2, closer correlation
r2 = 0.870, p < 0.001) was observed with an intercept of 0.311 and a
lope of 1.169. In patients with eGFR < 30 ml/min/1.73 m2 there was
 signiﬁcant but weaker correlation (r2 = 0.209, p < 0.001) between
og BNP and log NT-proBNP, with an intercept of 2.740 and a slope
f 0.481.
See Fig. S1 as supplementary ﬁle. Supplementary mate-
ial related to this article found, in the online version, at
ttp://dx.doi.org/10.1016/j.jjcc.2013.01.015.
ultiple regression analysis of log NT-proBNPIn patients with CKD stages 1–3, multiple regression analy-
is of log NT-proBNP showed signiﬁcant correlations (r2 = 0.892,
 < 0.001) with log BNP, LVEF, LVEDP, and heart rate. The equation
(pg/ml) = 2.740 + 0.481 × log BNP (pg/ml) (r2 = 0.209, p < 0.001). In all patients
(n  = 1083), log NT-proBNP (pg/ml) = 0.385 + 1.168 × log BNP (pg/ml) (r2 = 0.719,
p  < 0.001).
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eﬁning log NT-proBNP was as follows:
og NT-proBNP (pg/ml) = 0.643 + 1.164 × log BNP (pg/ml)
+ 0.002 × HR (bpm) − 0.001
× LVESVI (ml/m2) − 0.006 × LVEF (%)
− 0.007 × LVEDP (mmHg)
On the other hand, using only non-invasive variables, the equa-
ion deﬁning log NT-proBNP was as follows:
og NT-proBNP (pg/ml) = −0.34 + 1.161 × log BNP (pg/ml)
+ 0.002 × HR (bpm) + 0.002
× HR (bpm)
In patients with CKD stages 4–5, multiple regression analysis
f log NT-proBNP demonstrated signiﬁcant correlations (r2 = 0.707,
 < 0.001) with log BNP, LVEDP, eGFR, and BMI. The equation deﬁn-
ng log NT-proBNP was as follows:
og NT-proBNP (pg/ml) = 4.111 + 0.430 × log BNP (pg/ml)
+ 0.025 × LVEDP (mmHg) − 0.050
× eGFR (ml/min/1.73 m2) − 0.045
× BMI  (kg/m2)
Using only non-invasive variables, this equation was  as follows:
og NT-proBNP (pg/ml) = 4.080 + 0.479 × log BNP (pg/ml)
− 0.053 × eGFR (ml/min/1.73 m2)
− 0.030 × BMI  (kg/m2)
rognostic value of BNP and NT-proBNP
After a mean follow-up period of 51.9 months, all-cause deaths
nd cardiovascular events were analyzed in 1035 patients (95.6%).
verall, 132 patients died and 202 patients reached the compos-
te end point of overall mortality, cardiovascular events, or both
Supplemental Table 1). The ROC curves for all-cause deaths and
he composite end point are shown in Fig. 2. In patients with an
GFR ≥ 30 ml/min/1.73 m2, the area under the curve (AUC) for BNP
nd NT-proBNP were similar for predicting all-cause death and
he composite end point of cardiovascular events (Fig. 2A and B).
he optimal predictive values of plasma BNP and NT-proBNP levels
or all-cause death were 87.0 pg/ml (sensitivity, 0.712; speciﬁcity,
.769) and 258.6 pg/ml (0.769, 0.589), respectively. The corre-
ponding values for composite end points were 90.8 pg/ml (0.618,
.707) and 259.7 pg/ml (0.727, 0.608), respectively. However, in
atients with CKD stages 4–5, in the ROC for mortality the AUC for
NP was 0.713 and the AUC for NT-proBNP was 0.760 (Fig. 2C and
). The optimal cutoff point for all-cause death was 114.5 pg/ml
0.821, 0.526) for BNP and 5809.0 pg/ml (0.786, 0.632) for NT-
roBNP. The AUC for BNP was 0.666 and that for NT-proBNP was
.720. The optimal cutoff for composite end points was  157.0 pg/ml
0.649, 0.562) for BNP and 5111.5 pg/ml (0.757, 0.667) for NT-
roBNP. The ROC curves for composite end point without initiation
f hemodialysis are shown in Supplemental Fig. S2. As were the
ases of ROC curves for all-cause death and composite end points,
he AUC for BNP and NT-proBNP were approximately equal inlogy 61 (2013) 410–416
patients with CKD1–3, and in patients with CKD4–5 the AUC for
NT-proBNP was higher than BNP.
See Fig. S2 and Table S1 as supplementary ﬁles. Supplemen-
tary material related to this article found, in the online version,
at http://dx.doi.org/10.1016/j.jjcc.2013.01.015.
Discussion
The present study deﬁned the equation relating BNP and
NT-proBNP by measuring the plasma levels of both peptides simul-
taneously in the same samples collected from 1053 patients who
underwent elective cardiac catheterization for diagnosis and coro-
nary intervention. When simple linear regression analyses were
carried out to evaluate the relation between baseline plasma BNP
and NT-proBNP levels expressed as log-transformed data, scatter
plot points representing patients with an eGFR < 30 ml/min/1.73 m2
were apparently distributed differently compared with those from
patients with an eGFR ≥ 30 ml/min/1.73 m2. Therefore, the equa-
tions were calculated separately in patients with an eGFR of
≤30 ml/min/1.73 m2. A possible reason for the distinct distribu-
tion pattern of the plasma levels of the two  peptides in patients
with a lower eGFR is probably due to the difference in the peptides’
clearance mechanisms. BNP is speciﬁcally cleared by receptors or a
neutral endopeptidase, and non-speciﬁcally cleared by the kidney
[7]. In contrast, NT-proBNP is primarily cleared non-speciﬁcally by
the kidney. As shown in Table 2, differences in clearance mecha-
nisms also differentially affected clinical variables associated with
plasma levels of both peptides in the group of patients with
an eGFR ≤ 30 ml/min/1.73 m2. Given that high amounts of unpro-
cessed proBNP are circulating in patients with heart failure [23]
probably because of absolute or relative lower activity of processing
enzyme, corin, the differential processing process of proBNP in
disease states may  also affect the plasma levels and clinical signif-
icance of the peptides. Further studies are needed to understand
other mechanisms involved in plasma proﬁles of BNP and NT-
proBNP.
As shown in Fig. 2A and B, the ROC curves for BNP and
NT-proBNP were almost superimposed in patients with an
eGFR ≥ 30 ml/min/1.73 m2, suggesting that the prognostic value of
the peptides is similar. However, in the prediction of all-cause death
and cardiovascular events, the AUCs for NT-proBNP were greater
than those for BNP in patients with an eGFR < 30 ml/min/1.73 m2,
suggesting that the prognostic value of NT-proBNP is superior
to that of BNP in CKD stages 4 and 5. Optimal cutoff values
of BNP for all-cause death were 87.0 pg/ml in patients with an
eGFR ≥ 30 ml/min/1.73 m2, and 114.5 pg/ml in patients with an
eGFR < 30 ml/min/1.73 m2, so the optimal cutoff values differed
by 30% at the most. However, the optimal cutoff values of NT-
pro BNP for all-cause death were 258.6 pg/ml in patients with an
eGFR ≥ 30 ml/min/1.73 m2, and 5809.0 pg/ml in patients with an
eGFR < 30 ml/min/1.73 m2, so the former is less than one twenti-
eth of the latter. From a clinical point of view, it should be noted
that the optimal cutoff of NT-proBNP varied quite widely based on
renal function.
Limitations of the study
This was a single center observational study with a small
study population, especially in the subgroup of patients with an
eGFR < 30 ml/min/1.73 m2. Further multicenter, large-scale studies
are necessary to conﬁrm the equation relating BNP-NT-proBNP and
their prognostic values. Plasma BNP levels are currently measured
using commercially available kits produced by Shionogi, Abbott,
Mitsubishi, and so on. Levels of NT-proBNP are primarily measured
using a kit manufactured by Roche. The present study used Shionogi
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Fig. 2. Receiver operating characteristic curves for all-cause deaths and the composite end point. (A) For all-cause death in patients with CKD stages 1–3, cutoff values for
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onclusions
Both BNP and NT-proBNP are useful biomarkers for all-cause
eath and composite end points of cardiovascular events. The
quation relating BNP-NT-proBNP differed according to eGFR.
n patients with an eGFR ≥ 30 ml/min/1.73 m2, corresponding
o CKD stages 1–3, the prognostic value for all-cause death
nd cardiovascular events was similar for BNP and NT-proBNP,
ut NT-proBNP may  be superior to BNP in patients with an
GFR < 30 ml/min/1.73 m2.
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